At AbbVie, we partner to achieve two important outcomes: deliver innovative medicines and make a remarkable impact on people’s lives. 

AbbVie’s Partnering Days provide an opportunity to:

• Meet with our senior research and partnership leadership teams from the Corporate Strategy Office and R&D to discuss your ideas and research in a one-on-one setting

• Learn about our strategy, therapeutic areas of interest, and approach(s) to partnering 

• Share information about your company, pipeline, and discovery platforms with members of the R&D organization and Corporate Strategy Office of AbbVie. 

AbbVie Asia Capabilities:

• Headquarters situated within most Asian countries and regions including but not limited to China, Japan, S. Korea, Singapore, etc. with full supporting commercial, regulatory and medical affairs teams 

• Global manufacturing facility in Singapore

• Experienced in China cross-border deals (Jacobio, I-Mab Biopharma)

AbbVie is seeking to explore exciting new cross -border licensing opportunities with innovative biotechs in China/Asia.  Asian academics, VC, Biotechs also welcome to apply for 1:1 meetings or only to watch the General Session presentation. 

Selection Criteria for 1:1 Partnering

• Companies must have applied for a 1:1 meeting in advance and have been approved

• Project proposals will be evaluated based on project stage, strategic fit, and differentiation

Is there an application fee involved? 
There is no application fee.  We encourage all potential interested parties within the Asian Pacific life science ecosystem (i.e., biotechs, healthcare VCs, academics) to apply.

May I attend the showcase webinar only without applying for 1:1 Partnering?
Yes, absolutely.  The application process remains the same, please send an email to wendy.tai@abbvie.com.

Should I submit supporting documents with my application?
Yes. Please be sure to attach non-confidential supporting materials such as slide decks, poster presentations and/or research papers as part of your application. 

Please do not submit any confidential information as any submitted information be treated as non-confidential. Of course, we will use this information only internally for evaluation purposes and will not further distribute.

What types of cross boarder deals are of interest to AbbVie?
Depending on the asset and stage of development, AbbVie is flexible and experienced in terms of potential deal structure types (i.e., in-licensing, co-development, co-commercial, etc.).